share_log

bluebird bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.0%)

bluebird bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.0%)

bluebird bio | SC 13G：超過5%持股股東披露文件-BlackRock, Inc.(8.0%)
美股SEC公告 ·  11/09 03:31

牛牛AI助理已提取核心訊息

On September 30, 2024, BlackRock, Inc. filed a Schedule 13G with the Securities and Exchange Commission, disclosing an 8.0% ownership stake in bluebird bio, Inc., amounting to 15,443,767 shares. This filing indicates that BlackRock has sole voting power over 15,230,542 shares and sole dispositive power over all 15,443,767 shares. The filing was made under Rule 13d-1(b), identifying BlackRock as a parent holding company or control person. The address of bluebird bio's principal executive offices is listed as 455 Grand Union Boulevard, Somerville, MA 02145. The filing includes a certification by BlackRock, Inc. that the shares were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer. The document was signed by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on November 8, 2024.
On September 30, 2024, BlackRock, Inc. filed a Schedule 13G with the Securities and Exchange Commission, disclosing an 8.0% ownership stake in bluebird bio, Inc., amounting to 15,443,767 shares. This filing indicates that BlackRock has sole voting power over 15,230,542 shares and sole dispositive power over all 15,443,767 shares. The filing was made under Rule 13d-1(b), identifying BlackRock as a parent holding company or control person. The address of bluebird bio's principal executive offices is listed as 455 Grand Union Boulevard, Somerville, MA 02145. The filing includes a certification by BlackRock, Inc. that the shares were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer. The document was signed by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on November 8, 2024.
2024年9月30日，貝萊德公司向證券交易委員會提交了13G表，披露持有bluebird bio公司8.0％的股權，共計15,443,767股。此申報顯示，貝萊德擁有15,230,542股的獨立表決權，以及所有15,443,767股的獨立處置權。此申報是根據13d-1(b)規定進行的，將貝萊德確認爲母公司或控制人。bluebird bio的主要執行辦公室地址列在馬薩諸塞州薩默維爾大聯盟大道455號，郵編02145。申報中包括貝萊德公司的證書，證明這些股票是在業務常規過程中獲得的，而不是爲了改變或影響發行者的控制權。該文件於2024年11月8日由貝萊德公司的代理人斯賓塞·弗萊明簽署。
2024年9月30日，貝萊德公司向證券交易委員會提交了13G表，披露持有bluebird bio公司8.0％的股權，共計15,443,767股。此申報顯示，貝萊德擁有15,230,542股的獨立表決權，以及所有15,443,767股的獨立處置權。此申報是根據13d-1(b)規定進行的，將貝萊德確認爲母公司或控制人。bluebird bio的主要執行辦公室地址列在馬薩諸塞州薩默維爾大聯盟大道455號，郵編02145。申報中包括貝萊德公司的證書，證明這些股票是在業務常規過程中獲得的，而不是爲了改變或影響發行者的控制權。該文件於2024年11月8日由貝萊德公司的代理人斯賓塞·弗萊明簽署。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間